These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 36383908)

  • 1. Antibody-Drug Conjugates in Myeloid Leukemias.
    Senapati J; Daver NG; Pemmaraju N
    Cancer J; 2022 Nov-Dec 01; 28(6):454-461. PubMed ID: 36383908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin.
    Ricart AD
    Clin Cancer Res; 2011 Oct; 17(20):6417-27. PubMed ID: 22003069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical development of antibody-drug conjugates - lessons from leukaemia.
    Jabbour E; Paul S; Kantarjian H
    Nat Rev Clin Oncol; 2021 Jul; 18(7):418-433. PubMed ID: 33758376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining Biology and Chemistry for a New Take on Chemotherapy: Antibody-Drug Conjugates in Hematologic Malignancies.
    Ma H; Sawas A
    Curr Hematol Malig Rep; 2018 Dec; 13(6):555-569. PubMed ID: 30362019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-Drug Conjugates for the Treatment of Acute Pediatric Leukemia.
    Stokke JL; Bhojwani D
    J Clin Med; 2021 Aug; 10(16):. PubMed ID: 34441852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia.
    Jain N; O'Brien S; Thomas D; Kantarjian H
    Front Biosci (Elite Ed); 2014 Jan; 6(1):40-5. PubMed ID: 24389139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of Highly Optimized Antibody-Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia.
    Han YC; Kahler J; Piché-Nicholas N; Hu W; Thibault S; Jiang F; Leal M; Katragadda M; Maderna A; Dushin R; Prashad N; Charati MB; Clark T; Tumey LN; Tan X; Giannakou A; Rosfjord E; Gerber HP; Tchistiakova L; Loganzo F; O'Donnell CJ; Sapra P
    Clin Cancer Res; 2021 Jan; 27(2):622-631. PubMed ID: 33148666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigational Antibody-Drug Conjugates for Treatment of B-lineage Malignancies.
    Herrera AF; Molina A
    Clin Lymphoma Myeloma Leuk; 2018 Jul; 18(7):452-468.e4. PubMed ID: 29804872
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
    Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
    Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evolving Landscape of Antibody Drug Conjugates in Lymphoma.
    Prakash R; Subbiah V; Iyer SP
    Cancer J; 2022 Nov-Dec 01; 28(6):479-487. PubMed ID: 36383911
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antibody-drug conjugates: a new therapeutic class?].
    Chofflon I; Dietrich PY; Thang NN
    Rev Med Suisse; 2013 May; 9(387):1080-2, 1084-6. PubMed ID: 23757915
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma.
    Aujla A; Aujla R; Liu D
    Biomark Res; 2019; 7():9. PubMed ID: 31011424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ADCs Show Promise in Leukemias.
    Cancer Discov; 2016 Sep; 6(9):939. PubMed ID: 27388473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LILRB4-targeting Antibody-Drug Conjugates for the Treatment of Acute Myeloid Leukemia.
    Anami Y; Deng M; Gui X; Yamaguchi A; Yamazaki CM; Zhang N; Zhang CC; An Z; Tsuchikama K
    Mol Cancer Ther; 2020 Nov; 19(11):2330-2339. PubMed ID: 32879051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-Drug Conjugates: A Clinical Pharmacy Perspective on an Emerging Cancer Therapy.
    Jerjian TV; Glode AE; Thompson LA; O'Bryant CL
    Pharmacotherapy; 2016 Jan; 36(1):99-116. PubMed ID: 26799352
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the efficacy of ursodiol for prevention of hepatotoxicity in patients receiving gemtuzumab ozogamicin and inotuzumab ozogamicin.
    Sabatino D; Henneman A; Ahmad S; Jou E; Goldberg B
    J Oncol Pharm Pract; 2023 Jun; 29(4):840-845. PubMed ID: 35293248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The biology of MDR1-P-glycoprotein (MDR1-Pgp) in designing functional antibody drug conjugates (ADCs): the experience of gemtuzumab ozogamicin.
    Cianfriglia M
    Ann Ist Super Sanita; 2013; 49(2):150-68. PubMed ID: 23771260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical Characterization of Catabolic Pathways and Metabolism of ABBV-011, a Novel Calicheamicin-Based SEZ6-Targeting Antibody-Drug Conjugate.
    Ladror D; Gu C; Tong V; Schammel A; Gavrilyuk J; Haight A; Sarvaiya H
    Drug Metab Dispos; 2024 Jan; 52(2):135-142. PubMed ID: 38050039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calicheamicin Antibody-Drug Conjugates with Improved Properties.
    Vollmar BS; Frantz C; Schutten MM; Zhong F; Del Rosario G; Go MAT; Yu SF; Leipold DD; Kamath AV; Ng C; Xu K; Dela Cruz-Chuh J; Kozak KR; Chen J; Xu Z; Wai J; Adhikari P; Erickson HK; Dragovich PS; Polson AG; Pillow TH
    Mol Cancer Ther; 2021 Jun; 20(6):1112-1120. PubMed ID: 33722856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody-drug conjugate technology development for hematologic disorders.
    Bander NH; Czuczman MS; Younes A
    Clin Adv Hematol Oncol; 2012 Aug; 10(8 Suppl 10):1-16. PubMed ID: 23072775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.